Terms: = Lymphoma AND CARS, P49589, 833, ENSG00000110619 AND Prognosis
26 results:
1. Prediction model of radiotherapy outcome for Ocular Adnexal lymphoma using informative features selected by chemometric algorithms.
Zhou M; Wang J; Shi J; Zhai G; Zhou X; Ye L; Li L; Hu M; Zhou Y
Comput Biol Med; 2024 Mar; 170():108067. PubMed ID: 38301513
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic Value of
Luo Y; Huang Z; Gao Z; Wang B; Zhang Y; Bai Y; Wu Q; Wang M
Korean J Radiol; 2024 Feb; 25(2):189-198. PubMed ID: 38288898
[TBL] [Abstract] [Full Text] [Related]
3. Novel chimeric antigen receptor targets and constructs for acute lymphoblastic leukemia: Moving beyond CD19.
Acharya L; Garg A; Rai M; Kshetri R; Grewal US; Dhakal P
J Investig Med; 2024 Jan; 72(1):32-46. PubMed ID: 37497999
[TBL] [Abstract] [Full Text] [Related]
4. Clinical Applications of Flow Cytometry in Cancer Immunotherapies: From Diagnosis to Treatments.
Mishra HK
Methods Mol Biol; 2023; 2593():93-112. PubMed ID: 36513926
[TBL] [Abstract] [Full Text] [Related]
5. CAR-T therapy as a consolidation in remission B-ALL patients with poor prognosis.
Yin Z; Lin Y; Liu D; Tong C; Liu S
Cancer Rep (Hoboken); 2022 Oct; 5(10):e1706. PubMed ID: 35995579
[TBL] [Abstract] [Full Text] [Related]
6. CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell lymphoma and Therapeutic Options After CART19 Failure.
Caballero AC; Escribà-Garcia L; Alvarez-Fernández C; Briones J
Front Immunol; 2022; 13():904497. PubMed ID: 35874685
[TBL] [Abstract] [Full Text] [Related]
7. CAR T-cell therapy for relapsed/refractory non-Hodgkin's lymphoma: a comprehensive review.
St-Pierre F; Gordon LI
Clin Adv Hematol Oncol; 2022 May; 20(5):309-318. PubMed ID: 35579590
[TBL] [Abstract] [Full Text] [Related]
8. Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy.
An L; Lin Y; Deng B; Yin Z; Zhao D; Ling Z; Wu T; Zhao Y; Chang AH; Tong C; Liu S
BMC Cancer; 2022 Apr; 22(1):393. PubMed ID: 35410148
[TBL] [Abstract] [Full Text] [Related]
9. Clinicopathologic and Prognostic Significance of Bruton's Tyrosine Kinase Expression in Diffuse Large B-Cell lymphoma.
Han YB; Yang JM; Kwon HJ; Lee JO; Lee JS; Paik JH
Anticancer Res; 2021 Nov; 41(11):5677-5692. PubMed ID: 34732441
[TBL] [Abstract] [Full Text] [Related]
10. Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.
Liu S; Deng B; Yin Z; Lin Y; An L; Liu D; Pan J; Yu X; Chen B; Wu T; Chang AH; Tong C
Am J Hematol; 2021 Jun; 96(6):671-679. PubMed ID: 33725422
[TBL] [Abstract] [Full Text] [Related]
11. A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia.
Martino M; Alati C; Canale FA; Musuraca G; Martinelli G; Cerchione C
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670075
[TBL] [Abstract] [Full Text] [Related]
12. Chimeric antigen receptor T cell therapy for pediatric and young adult B cell acute lymphoblastic leukemia.
Myers RM; Dolan J; Teachey DT
Expert Rev Clin Immunol; 2020 Oct; 16(10):1029-1042. PubMed ID: 32975147
[TBL] [Abstract] [Full Text] [Related]
13. Efficacy and safety of CD19 CAR T constructed with a new anti-CD19 chimeric antigen receptor in relapsed or refractory acute lymphoblastic leukemia.
Gu R; Liu F; Zou D; Xu Y; Lu Y; Liu B; Liu W; Chen X; Liu K; Guo Y; Gong X; Lv R; Chen X; Zhou C; Zhong M; Wang H; Wei H; Mi Y; Qiu L; Lv L; Wang M; Wang Y; Zhu X; Wang J
J Hematol Oncol; 2020 Sep; 13(1):122. PubMed ID: 32894185
[TBL] [Abstract] [Full Text] [Related]
14. Molecular profiling of non-small cell lung cancer.
Forsythe ML; Alwithenani A; Bethune D; Castonguay M; Drucker A; Flowerdew G; French D; Fris J; Greer W; Henteleff H; MacNeil M; Marignani P; Morzycki W; Plourde M; Snow S; Xu Z
PLoS One; 2020; 15(8):e0236580. PubMed ID: 32756609
[TBL] [Abstract] [Full Text] [Related]
15. Study on the Prognostic Value of Aberrant Antigen in Patients With Acute B Lymphocytic Leukemia.
Liu J; Tan X; Ma YY; Liu Y; Gao L; Gao L; Kong P; Peng XG; Zhang X; Zhang C
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e349-e358. PubMed ID: 31076372
[TBL] [Abstract] [Full Text] [Related]
16. Tisagenlecleucel-T for the treatment of acute lymphocytic leukemia.
Thomas X; Paubelle E
Expert Opin Biol Ther; 2018 Nov; 18(11):1095-1106. PubMed ID: 30296188
[TBL] [Abstract] [Full Text] [Related]
17. Glycan-directed CAR-T cells.
Steentoft C; Migliorini D; King TR; Mandel U; June CH; Posey AD
Glycobiology; 2018 Sep; 28(9):656-669. PubMed ID: 29370379
[TBL] [Abstract] [Full Text] [Related]
18. [Characteristics and Prognostic Significance of Cytogenetic Abnormalities in Diffuse Large B-Cell lymphoma Patients with Bone Marrow Involvement].
Liu W; Lyu R; Huang WY; Li CW; Liu H; Li J; Zou DH; Qiu LG; Yi SH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):761-765. PubMed ID: 28641631
[TBL] [Abstract] [Full Text] [Related]
19. lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.
Kochenderfer JN; Somerville RPT; Lu T; Shi V; Bot A; Rossi J; Xue A; Goff SL; Yang JC; Sherry RM; Klebanoff CA; Kammula US; Sherman M; Perez A; Yuan CM; Feldman T; Friedberg JW; Roschewski MJ; Feldman SA; McIntyre L; Toomey MA; Rosenberg SA
J Clin Oncol; 2017 Jun; 35(16):1803-1813. PubMed ID: 28291388
[TBL] [Abstract] [Full Text] [Related]
20. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
Seo S; Hong JY; Yoon S; Yoo C; Park JH; Lee JB; Park CS; Huh J; Lee Y; Kim KW; Ryu JS; Kim SJ; Kim WS; Yoon DH; Suh C
Oncotarget; 2016 Nov; 7(47):76934-76943. PubMed ID: 27764777
[TBL] [Abstract] [Full Text] [Related]
[Next]
